Analysts Set Roche Holding AG (OTCMKTS:RHHBY) PT at $51.50

Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $51.50.

A number of research firms have recently issued reports on RHHBY. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. HSBC lowered Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Morgan Stanley upgraded Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target on the stock in a report on Friday, April 24th.

Get Roche alerts:

View Our Latest Stock Report on Roche

Roche Stock Down 0.2%

Roche stock traded down $0.12 during midday trading on Friday, hitting $51.90. 1,558,790 shares of the company’s stock were exchanged, compared to its average volume of 1,596,392. Roche has a 12 month low of $37.51 and a 12 month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The firm has a 50-day moving average of $51.35 and a two-hundred day moving average of $52.72.

Institutional Trading of Roche

Several hedge funds have recently modified their holdings of RHHBY. Curio Wealth LLC bought a new position in shares of Roche during the 3rd quarter worth approximately $25,000. McIlrath & Eck LLC acquired a new stake in Roche in the first quarter valued at approximately $39,000. Oakworth Capital Inc. grew its holdings in Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after purchasing an additional 285 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new position in Roche in the fourth quarter worth $192,000. Finally, Douglass Winthrop Advisors LLC acquired a new position in shares of Roche during the third quarter worth $201,000.

Roche Company Profile

(Get Free Report)

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

Featured Articles

• Five stocks we like better than Roche
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.